


Name: Eloralintide

Cat#: EX-A9589

Target: Amylin Receptor

Pathway: GPCR/G Protein

Chemical Structure:



Chemical Name

L-Tyrosinamide, L- γ -glutamyl-S-(mercaptomethyl)-L-cysteinyl-L-asparaginylyl-L-threonyl-L-alanyl-L-threonyl-L-cysteinyl-L-alanyl-L-threonylglycyl-L-ornithyl-L-leucyl-L-alanyl-L- α -glutamyl- α -methyl-L-phenylalanyl-L-leucyl-L-valyl-L-arginylyl-L-seryl-L-seryl-L-asparaginylyl-N2-methyl-L-asparaginylyl-L-phenylalanylglycyl-L-prolyl-N6-[N-(19-carboxy-1-oxononadecyl)-L-glyl-L-glyl]-L-lysyl-L-leucyl-L-prolyl-L-threonyl-L- α -glutamyl-L-valylyl-L-seryl-L-asparaginylyl-L-threonyl-, cyclic (2 \rightarrow 7)-thioether

Sequence	{γGlu}-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gly-{Orn}-Leu-Ala-Glu-{{α-Me-Phe}}-Leu-Val-Arg-Ser-Ser-Asn-{{(N-Me-Asn)}}-Phe-Gly-Pro-{Lys(γGlu-γGlu-C20 diacid)}-Leu-Pro-Pro-Thr-Glu-Val-Gly-Ser-Asn-Thr-Tyr-NH ₂ (Methylene bridge: Cys2-Cys7)
Sequence Shortening	{γGlu}-CNTATCATG-{Orn}-LAE-{{α-Me-Phe}}-LVRSSN-{{(N-Me-Asn)}}-FGP-{Lys(γGlu-γGlu-C20 diacid)}-LPPTVEGSNTY-NH ₂ (Methylene bridge: Cys2-Cys7)

Molecular Weight	4526.10	Storage	2 years -20°C powder
Formula	C201H319N49O65S2		1 month -20°C in solvent
CAS No.	2883634-40-8	Synonyms	LY3841136; AMY1176

Solubility (25°C) *	In vitro	DMSO	DMSO : H ₂ O
		Ethanol	N/A
		Water	N/A
	In vivo (should be freshly prepared each time)		

* <1 mg/ml means slightly soluble or insoluble.

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions:

Concentration \ Mass	Volume		
	1 mg	5 mg	10 mg
1 mM	0.2209 mL	1.1047 mL	2.2094 mL
5 mM	0.0442 mL	0.2209 mL	0.4419 mL
10 mM	0.0221 mL	0.1105 mL	0.2209 mL

DMSO : *The above data is based on the product molecular weight 4526.10.

Biological Activities:

Description	Eloralintide is an AMYR agonist, which is promising for research of type 2 diabetes and obesity ^[1] .
--------------------	--

References	[1]. A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With LY3841136 and Tirzepatide, Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes.
-------------------	---